PHARMACOKINETICS OF BILIARY EXCRETED ANGIOTENSIN CONVERTING ENZYME INHIBITOR, TEMOCAPRIL, IN DIABETIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 3B AND ABOVE
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: YASUDA, Gen (Yokohama City University Centre Hospital, Nephrology and Hypertension, Yokohama, Japan)
- Co-author(s): Gen Yasuda
In diabetic patients with chronic kidney disease (CKD) angiotensin converting enzyme inhibitors (ACEI) are the first option to reduce blood pressure. However, ACEI impair renal function in the presence of ischemic nephropathy. Temocapril, one of biliary excreted ACEI, is expected to be less accumulated. However, the pharmacokinetics during the.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.